CDK1 and pancreatic neoplasm: Figure8(d-f) showed that miR-488 inhibition enhanced, while SN50 treatment attenuated pancreatic tumor cell aggressiveness; the effects of SN50 treatment were significantly reversed by miR-488 inhibition. Regarding the protein levels of cell cycle regulators, miR-488 inhibition increased, while SN50 treatment decreased cyclin A, cyclin B, CDK1, and CDK2 protein contents; similarly, miR-488 inhibition significantly attenuated the effects of SN50 treatment (Figure8(g)).